AVR
Anteris Technologies Global Corp.
Medical - Devices
Market Cap$237M
5Y Perf.+17.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AVR vs XTNT vs NVCR vs GMED
Revenue, margins, valuation, and 5-year total return — side by side.
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$73M
5Y Perf.+17.4%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$2.04B
5Y Perf.-40.0%
GMED
Globus Medical, Inc.
Medical - Devices
Market Cap$10.54B
5Y Perf.-5.8%
AVR vs XTNT vs NVCR vs GMED — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AVR | XTNT | NVCR | GMED |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $237M | $73M | $2.04B | $10.54B |
| Revenue (TTM) | $2M | $133M | $674M | $3.10B |
| Net Income (TTM) | $-84M | $2M | $-173M | $587M |
| Gross Margin | 67.9% | 62.0% | 75.2% | 50.9% |
| Operating Margin | -40.2% | 4.8% | -27.2% | 17.2% |
| Forward P/E | — | — | — | 16.7x |
| Total Debt | $1M | $35M | $290M | $119M |
| Cash & Equiv. | $70M | $6M | $103M | $526M |
AVR vs XTNT vs NVCR vs GMED — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AVR
XTNT
NVCR
GMED
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Anteris Technologie… (AVR) | 100 | 117.9 | +17.9% |
| Xtant Medical Holdi… (XTNT) | 100 | 117.4 | +17.4% |
| NovoCure Limited (NVCR) | 100 | 60.0 | -40.0% |
| Globus Medical, Inc. (GMED) | 100 | 94.2 | -5.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AVR vs XTNT vs NVCR vs GMED
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTNT and GMED are tied at the top with 2 categories each — the right choice depends on your priorities. Globus Medical, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. AVR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
AVR
Anteris Technologies Global Corp.
The Defensive Pick
AVR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.14, Low D/E 2.2%, current ratio 4.51x
- +50.2% vs XTNT's -3.2%
Best for: sleep-well-at-night
XTNT
Xtant Medical Holdings, Inc.
The Income Pick
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.67
- Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
- 28.4% revenue growth vs AVR's -1.2%
- Beta 0.67 vs NVCR's 2.15, lower leverage
Best for: income & stability and growth exposure
NVCR
NovoCure Limited
The Secondary Option
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
GMED
Globus Medical, Inc.
The Long-Run Compounder
GMED is the #2 pick in this set and the best alternative if long-term compounding and defensive is your priority.
- 233.8% 10Y total return vs AVR's 17.5%
- Beta 1.23, current ratio 4.26x
- 18.9% margin vs AVR's -39.4%
- 11.3% ROA vs AVR's -442.1%
Best for: long-term compounding and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | XTNT | 28.4% revenue growth vs AVR's -1.2% |
| Quality / Margins | GMED | 18.9% margin vs AVR's -39.4% |
| Stability / Safety | XTNT | Beta 0.67 vs NVCR's 2.15, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | AVR | +50.2% vs XTNT's -3.2% |
| Efficiency (ROA) | GMED | 11.3% ROA vs AVR's -442.1% |
AVR vs XTNT vs NVCR vs GMED — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
Segment breakdown not available.
FY 2024
AVR vs XTNT vs NVCR vs GMED — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGMEDLAGGINGNVCR
Who Leads Where
GMED leads in 3 of 6 categories
XTNT leads 1 • AVR leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓NVCRNovoCure Limited
0leads
AVRAnteris Technologies …
0leads
XTNTXtant Medical Holding…
1leads
GMEDGlobus Medical, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs XTNTvs AVRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GMED4/6
Valuation MetricsMultiples, price ratios, and targets
XTNT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GMED7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
GMED3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GMED leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GMED is the larger business by revenue, generating $3.1B annually — 1449.5x AVR's $2M. GMED is the more profitable business, keeping 18.9% of every revenue dollar as net income compared to AVR's -39.4%. On growth, GMED holds the edge at +27.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $133M | $674M | $3.1B |
| EBITDAEarnings before interest/tax | -$84M | $11M | -$165M | $745M |
| Net IncomeAfter-tax profit | -$84M | $2M | -$173M | $587M |
| Free Cash FlowCash after capex | -$79M | $5M | -$48M | $605M |
| Gross MarginGross profit ÷ Revenue | +67.9% | +62.0% | +75.2% | +50.9% |
| Operating MarginEBIT ÷ Revenue | -40.2% | +4.8% | -27.2% | +17.2% |
| Net MarginNet income ÷ Revenue | -39.4% | +1.3% | -25.7% | +18.9% |
| FCF MarginFCF ÷ Revenue | -37.1% | +3.9% | -7.1% | +19.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -44.2% | +19.0% | +12.3% | +27.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -54.1% | +123.7% | -100.0% | +66.7% |
GMED leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
XTNT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| Market CapShares × price | $237M | $73M | $2.0B | $10.5B |
| Enterprise ValueMkt cap + debt − cash | $168M | $102M | $2.2B | $10.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.75x | -4.33x | -14.66x | 19.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 16.70x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.64x |
| EV / EBITDAEnterprise value multiple | — | — | — | 16.90x |
| Price / SalesMarket cap ÷ Revenue | 87.79x | 0.62x | 3.11x | 3.59x |
| Price / BookPrice ÷ Book value/share | 2.13x | 1.62x | 5.86x | 2.34x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 17.91x |
XTNT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
GMED leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
GMED delivers a 13.0% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-25 for AVR. AVR carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), GMED scores 9/9 vs XTNT's 2/9, reflecting strong financial health.
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -25.1% | +3.8% | -50.8% | +13.0% |
| ROA (TTM)Return on assets | -4.4% | +1.8% | -16.5% | +11.3% |
| ROICReturn on invested capital | — | -12.8% | -16.4% | +8.9% |
| ROCEReturn on capital employed | -183.9% | -17.9% | -28.9% | +10.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 5 | 9 |
| Debt / EquityFinancial leverage | 0.02x | 0.82x | 0.85x | 0.03x |
| Net DebtTotal debt minus cash | -$69M | $29M | $187M | -$408M |
| Cash & Equiv.Liquid assets | $70M | $6M | $103M | $526M |
| Total DebtShort + long-term debt | $1M | $35M | $290M | $119M |
| Interest CoverageEBIT ÷ Interest expense | -816.06x | 1.55x | -96.80x | 81.13x |
GMED leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
GMED leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVR five years ago would be worth $11,750 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, AVR leads with a +50.2% total return vs XTNT's -3.2%. The 3-year compound annual growth rate (CAGR) favors GMED at 10.2% vs NVCR's -36.4% — a key indicator of consistent wealth creation.
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +33.7% | -30.7% | +36.4% | -10.7% |
| 1-Year ReturnPast 12 months | +50.2% | -3.2% | +2.6% | +7.6% |
| 3-Year ReturnCumulative with dividends | +17.5% | -20.0% | -74.2% | +34.0% |
| 5-Year ReturnCumulative with dividends | +17.5% | -68.9% | -90.2% | +9.7% |
| 10-Year ReturnCumulative with dividends | +17.5% | -98.0% | +38.5% | +233.8% |
| CAGR (3Y)Annualised 3-year return | +5.5% | -7.2% | -36.4% | +10.2% |
GMED leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AVR and XTNT each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVR currently trades 94.7% from its 52-week high vs XTNT's 54.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.14x | 0.67x | 2.15x | 1.23x |
| 52-Week HighHighest price in past year | $6.95 | $0.95 | $20.06 | $101.40 |
| 52-Week LowLowest price in past year | $2.85 | $0.44 | $9.82 | $51.79 |
| % of 52W HighCurrent price vs 52-week peak | +94.7% | +54.7% | +89.2% | +76.9% |
| RSI (14)Momentum oscillator 0–100 | 63.4 | 58.6 | 70.9 | 36.8 |
| Avg Volume (50D)Average daily shares traded | 800K | 147K | 1.4M | 1.1M |
Evenly matched — AVR and XTNT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AVR as "Buy", NVCR as "Buy", GMED as "Buy". Consensus price targets imply 128.0% upside for AVR (target: $15) vs 41.5% for GMED (target: $110).
| Metric | AVRAnteris Technolog… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | GMEDGlobus Medical, I… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | — | $33.50 | $110.29 |
| # AnalystsCovering analysts | 1 | — | 15 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +2.8% |
Insufficient data to determine a leader in this category.
Key Takeaway
GMED leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTNT leads in 1 (Valuation Metrics). 1 tied.
Best OverallGlobus Medical, Inc. (GMED)Leads 3 of 6 categories
Loading custom metrics...
AVR vs XTNT vs NVCR vs GMED: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AVR or XTNT or NVCR or GMED a better buy right now?
For growth investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus -1. 2% for Anteris Technologies Global Corp. (AVR). Globus Medical, Inc. (GMED) offers the better valuation at 19. 9x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Anteris Technologies Global Corp. (AVR) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AVR or XTNT or NVCR or GMED?
Over the past 5 years, Anteris Technologies Global Corp.
(AVR) delivered a total return of +17. 5%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: GMED returned +233. 8% versus XTNT's -98. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AVR or XTNT or NVCR or GMED?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 67β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 219% more volatile than XTNT relative to the S&P 500. On balance sheet safety, Anteris Technologies Global Corp. (AVR) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — AVR or XTNT or NVCR or GMED?
By revenue growth (latest reported year), Xtant Medical Holdings, Inc.
(XTNT) is pulling ahead at 28. 4% versus -1. 2% for Anteris Technologies Global Corp. (AVR). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -194. 5% for Anteris Technologies Global Corp.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AVR or XTNT or NVCR or GMED?
Globus Medical, Inc.
(GMED) is the more profitable company, earning 18. 3% net margin versus -28. 2% for Anteris Technologies Global Corp. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -29. 0% for AVR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AVR or XTNT or NVCR or GMED more undervalued right now?
Analyst consensus price targets imply the most upside for AVR: 128.
0% to $15. 00.
07Which pays a better dividend — AVR or XTNT or NVCR or GMED?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is AVR or XTNT or NVCR or GMED better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67)). Anteris Technologies Global Corp. (AVR) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTNT: -98. 0%, AVR: +17. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AVR and XTNT and NVCR and GMED?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AVR is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AVR: -44.2% · XTNT: 19.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.